Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 72162-1058

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 72162-1058). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

FDA Label Image

Figure6 (Image 10)

This text provides information about different dosages of Duloretine and a Placebo treatment. The dosages mentioned are 120 mg, 60 mg, and 20 mg once daily. The document also refers to the percentage of patients improved and shows a progression in pain relief from baseline measurements.*

FDA Label Image

Figure 7 (Image 11)

This text provides a graph displaying the percentage of patients improved with Duloxetine Delayed-Release 60mg Once Daily compared to Placebo. The graph shows the improvement in pain from baseline ranging from 10% to 100%.*

FDA Label Image

Figure8 (Image 12)

This text is displaying the percentage of patients who improved while taking Placebo versus Duloxetine Delayed-Release at doses of 60 mg/120 mg once daily. It shows the percentage of improvement in pain from the baseline data.*

FDA Label Image

Figure9 (Image 13)

This is a chart showing the percentage of patients improved with a placebo compared to those taking Duloxetine Delayed-Release at a dosage of 60 mg once daily. The data represents the percent improvement in pain from baseline using the BOCF method. The chart depicts the progression of improvement over time.*

FDA Label Image

Figure10 (Image 14)

This text provides information on the percentage of patients improved with Duloxetine Delayed-Release compared to a placebo. The graph displays numbers representing percent improvement in pain from baseline using the drug at 60/120 mg Once Daily.*

FDA Label Image

1 (Image 2)

FDA Label Image

1 (Image 3)

FDA Label Image

1 (Image 4)

FDA Label Image

Figure1 (Image 5)

This chart displays the proportion of patients with relapse over time based on the treatment received, either Placebo or Duloxetine Delayed-Release Capsules. The x-axis represents the time from randomization to relapse in days, while the y-axis shows the percentage of patients experiencing relapse. The data point at day 0 indicates the start of the study. The Kaplan-Meier estimator method was used to calculate the relapse rates for each treatment group.*

FDA Label Image

Figure2 (Image 6)

This text is displaying a graph showing the proportion of patients experiencing a relapse over time for two treatments: placebo and Duloxetine Delayed-Release Capsules. The graph indicates the time from randomization to relapse in days, with the x-axis displaying time and the y-axis showing the proportion of patients. The Kaplan-Meier estimator method is used for survival analysis.*

FDA Label Image

Figure3 (Image 7)

This text appears to be showing a comparison of the percentage of patients improved with different doses of duloxetine and placebo. The chart displays the percentage of improvement in pain from the baseline for Duloxetine 80mg, 60mg, 20mg, and a placebo. It can be used to evaluate and compare the effectiveness of different doses of duloxetine in managing pain.*

FDA Label Image

Figure4 (Image 8)

This text provides data on the percentage of patients improved in terms of pain after taking different doses of duloxetine and placebo. It compares the percent improvement in pain from baseline between Duloxetine 60mg twice a day, Duloxetine 60mg once a day, and Placebo.*

FDA Label Image

Figure5 (Image 9)

The text provides data on the percentage of patients improved for Duloxetine 60 mg Twice Daily, Duloxetine 60 mg Once Daily, and Placebo, with additional information indicating the percent improvement in pain from baseline.*

FDA Label Image

Label (Lbl721621058)

Each delayed-release capsule contains 67.3 mg of Duloxetine Hydrochloride, USP, which is equivalent to 60 mg Duloxetine. This medication is to be stored at 25°C (77°F) with excursions permitted to 15° to 30°C (59° to 86°F). It should be kept out of reach of children and dispensed in a tight, light-resistant container. Pharmacists are advised to dispense the Medication Guide to each patient along with the package insert.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.